{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:08:25Z","timestamp":1771211305751,"version":"3.50.1"},"reference-count":10,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors (ICIs) targeting cancer cells that evade immune T-cell regulation have revolutionized the treatment of metastatic carcinomas. Unfortunately, secondary endocrinopathies associated with ICI, including adrenal insufficiency, primary hypothyroidism, autoimmune diabetes, and rarely hypoparathyroidism, are increasing. Lipodystrophy, presumably due to the autoimmune destruction of adipocytes, leading to metabolic complications, is a less recognized adverse effect of ICI therapy. We present a case of a 66-year-old Caucasian woman treated with pembrolizumab, an anti-programmed death 1 inhibitor, for metastatic lung adenocarcinoma. Fifteen months after the treatment initiation, she was found to have hyperglycemia, hyperlipidemia, and hepatic steatosis but without any evidence of autoimmune diabetes. She was also noted to have isolated buccal fat pad loss, raising suspicion of acquired lipodystrophy. Despite well-preserved subcutaneous fat over the trunk and limbs, she had undetectable serum leptin levels. Whole-body fluorodeoxyglucose (FDG)-positron emission tomography scan showed diffuse mild FDG activity throughout the subcutaneous tissue, suggesting underlying inflammation. Over the next 3 months, she developed progressive fat loss leading to generalized lipodystrophy. Adipose tissue dysfunction, secondary to ICI-induced subclinical panniculitis, precedes overt fat loss and is characterized by hypoleptinemia and metabolic abnormalities.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad025","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T18:35:36Z","timestamp":1678386936000},"source":"Crossref","is-referenced-by-count":13,"title":["Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8103-0815","authenticated-orcid":false,"given":"Maheswaran","family":"Dhanasekaran","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashi","family":"Sandooja","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra S","family":"Higgins","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-2832","authenticated-orcid":false,"given":"Vinaya","family":"Simha","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Mayo Clinic , Rochester, MN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"1","key":"2024010813072392900_luad025-B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"issue":"7","key":"2024010813072392900_luad025-B2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2024010813072392900_luad025-B3","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1210\/jc.2018-02221","article-title":"Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma","volume":"104","author":"Falcao","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2024010813072392900_luad025-B4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.2337\/dc18-2535","article-title":"Acquired generalized lipodystrophy: a new cause of anti-PD-1 immune-related diabetes","volume":"42","author":"Jehl","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"2024010813072392900_luad025-B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/bjd.18124","article-title":"Acquired generalized lipodystrophy under immune checkpoint inhibition","volume":"182","author":"Haddad","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"2024010813072392900_luad025-B6","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.4158\/ACCR-2019-0234","article-title":"A case of acquired generalized lipodystrophy associated with pembrolizumab in a patient with metastatic malignant melanoma","volume":"6","author":"Bedrose","year":"2020","journal-title":"AACE Clin Case Rep"},{"issue":"6","key":"2024010813072392900_luad025-B7","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/CMR.0000000000000660","article-title":"Acquired lipodystrophy associated with immune checkpoint inhibitors","volume":"30","author":"Gnanendran","year":"2020","journal-title":"Melanoma Res"},{"issue":"12","key":"2024010813072392900_luad025-B8","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/L19-0635","article-title":"Lipodystrophic nonalcoholic fatty liver disease induced by immune checkpoint blockade","volume":"172","author":"Eigentler","year":"2020","journal-title":"Ann Intern Med"},{"issue":"4","key":"2024010813072392900_luad025-B9","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ecl.2016.06.012","article-title":"Lipodystrophy syndromes","volume":"45","author":"Hussain","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"2024010813072392900_luad025-B10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/01.mol.0000217898.52197.18","article-title":"Lipodystrophy: lessons in lipid and energy metabolism","volume":"17","author":"Simha","year":"2006","journal-title":"Curr Opin Lipidol"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/2\/luad025\/51825179\/luad025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/2\/luad025\/51825179\/luad025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:32:04Z","timestamp":1704720724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad025\/7074443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,17]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad025","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,2,17]]},"article-number":"luad025"}}